Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
10 papers
Recent·Most cited
A. Roy, L. Shi, A. Chang, X. Dong, A. Fernandez, J. C. Kraft, J. Li, V. Q. Le, R. V. Winegar, G. M. Cherf, D. Slocum, P. D. Poulson, G. E. casper, M. L. Vallecillo-Zuniga, J. C. Valdoz, , D. Baker
This paper designs highly selective miniprotein inhibitors for integrins αvβ6 and αvβ8 with picomolar affinity and therapeutic potential in a mouse fibrosis model.
bioRxiv · Jun 12, 2023 · PreprintBiochemistry
E. C. Yang, R. Divine, M. C. Miranda, A. J. Borst, W. Sheffler, J. Z. Zhang, J. Decarreau, A. Sarajovi, M. Abedi, N. Goldbach, M. Ahlrichs, C. Dobbins, A. Hand, S. Cheng, M. Lamb, , D. Baker
This paper designs pH-responsive antibody nanoparticles with three distinct protein components that disassemble at tunable pH levels, enabling targeted delivery of biologics.
bioRxiv · Apr 17, 2023Bioengineering
N. P. Bethel, A. J. Borst, F. Parmeggiani, M. J. Bick, T. Brunette, H. Nguyen, A. Kang, A. K. Bera, L. Carter, M. C. Miranda, R. Kibler, M. Lamb, X. Li, B. Sankaran, D. Baker
The paper designs extendable protein multiplexes with symmetric architectures to create precisely patterned nanofibers through controlled repeat propagation and hydrophilic patch placement.
bioRxiv · Oct 14, 2022 · PreprintBioengineering
J. Y. Wang, A. Khmelinskaia, W. Sheffler, M. C. Miranda, A. Antanasijevic, A. J. Borst, S. V. Torres, C. Shu, Y. Hsia, U. Nattermann, D. Ellis, C. Walkey, M. Ahlrichs, S. Chan, A. Kang, , N. P. King
This study identifies cryptic transmembrane domains in designed protein nanoparticles that hinder secretion and introduces a computational tool, Degreaser, to remove them while maintaining stability, improving secretion efficiency.
bioRxiv · Aug 4, 2022Biochemistry
P. S. Arunachalam, Y. Feng, U. Ashraf, M. Hu, V. V. Edara, V. I. Zarnitsyna, P. P. Aye, N. Golden, K. W. M. Green, B. M. Threeton, N. J. Maness, B. J. Beddingfield, R. P. Bohm, J. Dufour, K. Russell-Lodrigue, , B. Pulendran
This study shows that an adjuvanted subunit vaccine provides durable protection against SARS-CoV-2 Omicron in non-human primates, with strong neutralizing antibodies and memory T/B cells after booster doses.
bioRxiv · Mar 18, 2022 · PreprintImmunology
A. C. Walls, L. A. VanBlargan, K. Wu, A. Choi, M. J. Navarro, D. Lee, L. Avena, D. M. Berrueta, M. N. Pham, S. Elbashir, M. C. Miranda, E. Kepl, M. Johnson, A. Blackstone, K. R. Sprouse, , D. Veesler
This study compares neutralizing antibody responses to SARS-CoV-2 variants in vaccinated humans and mice, finding that mice do not accurately reflect the breadth and potency seen in humans.
bioRxiv · Feb 7, 2022Immunology
M. McCallum, A. C. Walls, K. R. Sprouse, J. E. Bowen, L. Rosen, H. V. Dang, A. deMarco, N. Franko, S. W. Tilles, J. Logue, M. C. Miranda, M. Ahlrichs, L. Carter, G. Snell, M. S. Pizzuto, , D. Veesler
This study investigates how delta and kappa SARS-CoV-2 variants evade immune responses by altering antigenic sites and reducing ACE2 binding affinity.
Science · Dec 24, 2021Peer-reviewedImmunology
A. C. Walls, M. C. Miranda, M. N. Pham, A. Schaefer, A. Greaney, P. S. Arunachalam, M.-J. Navarro, M. A. Tortorici, K. Rogers, M. A. O'Connor, L. Shireff, D. E. Ferrell, N. Brunette, E. Kepl, J. E. Bowen, , Veesler
This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.
bioRxiv · Mar 15, 2021Immunology
P. S Arunachalam, A. C. Walls, N. Golden, C. Atyeo, S. Fischinger, C. Li, P. Aye, M. J. Navarro, L. Lai, V. V. Edara, K. Roltgen, K. Rogers, L. Shirreff, D. E. Ferrell, S. Wrenn, , Coffma
This study evaluates adjuvants for a subunit SARS-CoV-2 nanoparticle vaccine in non-human primates, showing durable neutralizing antibody responses and protection against infection.
bioRxiv · Feb 10, 2021 · PreprintImmunology
A. C. Walls, B. Fiala, A. Schaefer, S. Wrenn, M. N. Pham, M. Murphy, L. V. Tse, L. Shehata, M. A. O'Connor, C. Chen, M. J. Navarro, M. C. Miranda, D. Pettie, R. Ravichandran, J. C. Kraft, , N. P. King
This study designs SARS-CoV-2 nanoparticle vaccines that induce strong neutralizing antibodies in mice, with higher titers and lower doses than existing trimer vaccines.
bioRxiv · Aug 11, 2020Immunology